Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Kim, Minseok S ^a   Kim, Taemin ^a   Kong, Sun Young ^b   Kwon, Soim ^c   Bae, Chae Yun ^a   Choi, Jaekyu ^a   Kim, Chul Hwan ^c   Lee, Eun Sook ^c   Park, Je Kyun ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b National Cancer Center   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ANALYTICAL EQUIPMENT; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER DIAGNOSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EQUIPMENT DESIGN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICROFLUIDIC ANALYSIS; NEEDLE BIOPSY; PROCESS CONTROL; QUANTITATIVE ANALYSIS; REACTION TIME; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BIOLOGICAL MODEL; BIOPSY; BREAST; BREAST TUMOR; CANCER STAGING; FEMALE; METHODOLOGY; MICROFLUIDICS; PATHOLOGY; REPRODUCIBILITY; STAINING;

BIOPSY; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFLUIDICS; MODELS, BIOLOGICAL; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING;

EID: 77953775921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010441     Document Type: Article

References (45)

1. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA (2006) Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 6: 886-893.
2. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, et al. (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68: 645-649.
3. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856.
4. van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564-570.
5. Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448: 744-755.
6. Wang HN, Vo-Dinh T (2009) Multiplex detection of breast cancer biomarkers using plasmonic molecular sentinel nanoprobes. Nanotechnology 20: 65101.
7. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
8. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
10. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
12. Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275.
13. Walker RA (2006) Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology 49: 406-410.
14. Lakhani SR, Ashworth A (2001) Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1: 151-157.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
16. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al. (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146.
17. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
18. Wu X, Liu H, Liu J, Haley KN, Treadway JA, et al. (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21: 41-46.
19. Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, et al. (2004) Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 22: 198-203.
20. Fountaine TJ, Wincovitch SM, Geho DH, Garfield SH, Pittaluga S (2006) Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod Pathol 19: 1181-1191.
21. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, et al. (2006) Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7: 657-667.
22. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, et al. (2007) Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2: 1152-1165.
23. Sweeney E, Ward TH, Gray N, Womack C, Jayson G, et al. (2008) Quantitative multiplexed quantum dot immunohistochemistry. Biochem Biophys Res Commun 374: 181-186.
24. Kim MS, Yeon JH, Park JK (2007) A microfluidic platform for 3-dimensional cell culture and cell-based assays. Biomed Microdevices 9: 25-34.
25. Yeon JH, Park JK (2007) Microfluidic cell culture systems for cellular analysis. Biochip J 1: 17-27.
26. El-Ali J, Sorger PK, Jensen KF (2006) Cells on chips. Nature 442: 403-411.
27. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235-1239.
28. Kim MS, Lee W, Kim YC, Park JK (2008) Microvalve-assisted patterning platform for measuring cellular dynamics based on 3D cell culture. Biotechnol Bioeng 101: 1005-1013.
29. Yeon JH, Park JK (2009) Drug Permeability Assay Using Microhole-Trapped Cells in a Microfluidic Device. Anal Chem 81: 1944-1951.
30. Liu GL, Kim J, Lu Y, Lee LP (2006) Optofluidic control using photothermal nanoparticles. Nat Mater 5: 27-32.
31. Hahn YK, Jin Z, Kang JH, Oh E, Han MK, et al. (2007) Magnetophoretic immunoassay of allergen-specific IgE in an enhanced magnetic field gradient. Anal Chem 79: 2214-2220.
32. Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry- issues concerning methods, utility and semiquantitative assessment II. Histopathology 49: 411-424.
33. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
34. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, et al. (2002) Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441: 328-334.
35. Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, et al. (2009) A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 20: 1193-1198.
36. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 96: 329-335.
37. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14: 4168-4174.
38. Nocito A, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 94: 1-5.
39. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, et al. (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17: 790-797.
40. Halushka MK, Cornish TC, Lu J, Selvin S, Selvin E (2009) Creation, validation, and quantitative analysis of protein expression in vascular tissue microarrays. Cardiovasc Pathol;doi: 10.1016/j.carpath.2008.12.007.
41. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26: 312-319.
42. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847.
43. Hassan S, Ferrario C, Mamo A, Basik M (2008) Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol 19: 19-25.
44. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, et al. (2009) A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 124: 2124-2134.
45. Netto GJ, Watkins DL, Williams JW, Colby TV, dePetris G, et al. (2006) Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multiinstitutional trial experience. Arch Pathol Lab Med 130: 1157-1162.